News Sentiment

NEUP sentiment intelligence

Neuphoria Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.54 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

73/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+4.7% over one week, -19.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Number of shareholders of Neuphoria Therapeutics Inc. – NASDAQ:NEUP

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 73/100 classification
One-week reaction 4.7% Price confirming higher
Trend fit Trend inactive -19.0% over four weeks
Fair value -40.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 28
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 8
TradingKey 6
simplywall.st 3
Finviz 2
Investing.com 2
Moomoo 2
Stocktwits 1

Event Lens

What the news is about

Classified themes
Earnings 15
Market update 15
Deals and strategy 8
Analyst action 3
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 43
TradingView Direct company coverage

Number of shareholders of Neuphoria Therapeutics Inc. – NASDAQ:NEUP

This article provides details on the number of shareholders for Neuphoria Therapeutics Inc. (NASDAQ: NEUP). It indicates that the information is presented by period, value, change, and change percentage, with data sourced from FactSet Research Systems Inc.

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 02:39
Source
TradingView
Finviz Direct company coverage

NEUP - Neuphoria Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial data for Neuphoria Therapeutics Inc. It includes detailed information on the company's market performance, key financial ratios, insider and institutional ownership, and stock performance metrics. The data c

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 16:41
Source
Finviz
Stocktwits Direct company coverage

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

Merck (MRK) shares dropped over 2% and Neuphoria Therapeutics (NEUP) fell 19% after Merck terminated a mid-stage trial for its Alzheimer's drug, MK-1167, citing business reasons due to insufficient performance. This marks a second discontinuation for a drug developed under their

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jul 2026 18:01
Source
Stocktwits
Fierce Biotech Direct company coverage

Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms

Merck has discontinued a phase 2 study for its Alzheimer's disease candidate, MK-1167, due to underwhelming efficacy in an interim analysis. This marks another setback for Merck's partner, Neuphoria Therapeutics, which recently faced a failed phase 3 trial for a social anxiety ca

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 14:35
Source
Fierce Biotech
Investing.com Direct company coverage

Neuphoria confirms merger talks with Scancell Holdings

Neuphoria Therapeutics Inc. confirmed it is in discussions with Scancell Holdings plc regarding a potential acquisition, which would make Scancell a Nasdaq-listed company. The discussions follow speculation in the UK press and come after Neuphoria's lead drug candidate, BNC210, f

Tone
Neutral 50/100
Event
Deals and strategy
Published
30 Jun 2026 17:42
Source
Investing.com
Market source Direct company coverage

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics Inc. has confirmed it is in discussions with London-listed Scancell Holdings plc regarding a potential acquisition. The talks were prompted by speculation in the UK press and an announcement from Scancell. While discussions are ongoing, Neuphoria emphasizes

Tone
Positive 61/100
Event
Deals and strategy
Published
28 Jun 2026 16:42
Source
Market source
TradingView Direct company coverage

Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell

Neuphoria Therapeutics has confirmed it is in discussions regarding a potential acquisition by Scancell. The brief report, sourced from Reuters via Refinitiv, indicates that further details were not immediately available beyond the confirmation of these talks.

Tone
Positive 66/100
Event
Deals and strategy
Published
26 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Neuphoria Therapeutics Inc. Actuals & Estimates (NASDAQ:NEUP)

This article provides an overview of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) stock, including its current price, market capitalization, and historical performance. It details financial estimates, such as earnings per share and revenue, and notes that the company does not pay d

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 20:09
Source
TradingView
Market source Direct company coverage

Scancell confirms advanced talks over reverse merger with Neuphoria

Scancell Holdings PLC, a developer of cancer immunotherapies, has confirmed it is in advanced discussions for a reverse merger with US-listed Neuphoria Therapeutics. The all-share transaction could provide Scancell with a Nasdaq listing, enhancing its profile among US investors.

Tone
Positive 66/100
Event
Deals and strategy
Published
26 Jun 2026 14:09
Source
Market source
TradingView Direct company coverage

NEUP Forecast — Price Target — Prediction for 2027

This article provides an overview of Neuphoria Therapeutics Inc. (NEUP) stock, including its current price, market capitalization, and historical performance. It details recent earnings and revenue figures, upcoming earnings dates, and general advice on investing in NEUP stock. T

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 14:09
Source
TradingView
Investing.com Direct company coverage

Scancell in talks for reverse merger with Neuphoria Therapeutics

Scancell Holdings plc is in advanced discussions for a potential reverse merger with Neuphoria Therapeutics Inc., an all-share transaction aimed at facilitating a Nasdaq listing for Scancell. This move would enhance Scancell's profile with U.S. investors and includes plans for eq

Tone
Positive 65/100
Event
Deals and strategy
Published
26 Jun 2026 14:09
Source
Investing.com
TradingKey Direct company coverage

Neuphoria Therapeutics Inc (NEUP) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Neuphoria Therapeutics Inc (NEUP), detailing its current price momentum score, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently ranks low in the Biotechnology & Medi

Tone
Negative 40/100
Event
Market update
Published
24 Jun 2026 12:40
Source
TradingKey
TradingKey Direct company coverage

Neuphoria Therapeutics Inc (NEUP) Institutional Confidence

This article provides details on the institutional confidence in Neuphoria Therapeutics Inc (NEUP), listing major shareholders and their recent activity. It shows various institutional investors, their shareholdings, and the percentage change in their positions, highlighting sign

Tone
Positive 70/100
Event
Market update
Published
18 Jun 2026 22:09
Source
TradingKey
TradingKey Direct company coverage

Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Neuphoria Therapeutics Inc (NEUP) stock information, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The current stock

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 15:39
Source
TradingKey
TradingKey Direct company coverage

Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Neuphoria Therapeutics Inc (NEUP), covering business segments and regional contributions. As of March 4, 2025, the company has not disclosed relevant data for FY2019 and FY2020. The only regional revenue reported is from Australia, am

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 11:39
Source
TradingKey
TradingKey Direct company coverage

Neuphoria Therapeutics Inc (NEUP) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Neuphoria Therapeutics Inc (NEUP), noting its current valuation score of 8.32 and its ranking within the Biotechnology & Medical Research industry. It highlights the stock's P/E ratio and mentions that relevant data for P/B, P/S, and

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Neuphoria Therapeutics Inc (NEUP) has an earnings forecast score of 8.00 and an average price target of $20.00, according to analyst ratings. One analyst has a "Hold" rating for the stock, with a target price indicating a 63.55% upside. The company's EPS for the previous quarter

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 01:39
Source
TradingKey
TradingView Direct company coverage

Neuphoria Therapeutics Inc. Financial Disclosures & SEC Filings

This article provides an overview of Neuphoria Therapeutics Inc.'s SEC filings and other key documents, detailing the company's financial performance, operational updates, and clinical trial progress for its NEUP stock. It highlights significant events such as the pausing of R&D,

Tone
Negative 30/100
Event
Market update
Published
10 Jun 2026 06:39
Source
TradingView
Quartr Direct company coverage

Neuphoria Therapeutics (NEUP) Registration filing Summary

Neuphoria Therapeutics (NEUP) has filed a registration summary detailing its business as a clinical-stage biopharmaceutical company focused on CNS disorders. The company's lead candidate, BNC210, targets PTSD and SAD, and it has a strategic partnership with Merck. The filing also

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jun 2026 23:11
Source
Quartr
Finviz Direct company coverage

NEUP - Neuphoria Therapeutics Inc Stock Price and Quote

This page provides detailed stock information for Neuphoria Therapeutics Inc. (NEUP), including its last close price, financial metrics, analyst ratings, and a chronological list of company news and press releases. Key recent events include discussions regarding a potential rever

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jun 2026 03:09
Source
Finviz
The Globe and Mail Direct company coverage

Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial

Neuphoria Therapeutics (NEUP) recently received an AUD $1.416 million milestone payment from Pfizer related to the KAT6 program, triggered by the first dosing in a Phase III trial for metastatic breast cancer. This payment contributes to the AUD $3.52 million Neuphoria has receiv

Tone
Positive 63/100
Event
Earnings
Published
26 May 2026 11:39
Source
The Globe and Mail
Moomoo Direct company coverage

H.C. Wainwright Maintains Neuphoria Therapeutics(NEUP.US) With Hold Rating

This article states that H.C. Wainwright has maintained its Hold rating on Neuphoria Therapeutics (NEUP.US). No additional details or analysis are provided in the current document.

Tone
Neutral 50/100
Event
Analyst action
Published
18 May 2026 01:39
Source
Moomoo
www.marketscreener.com Direct company coverage

Neuphoria Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026

Neuphoria Therapeutics Inc. has reported its financial results for the third quarter and nine months ended March 31, 2026. The company posted a net loss of USD 0.505063 million for the third quarter, a significant decline from a net income of USD 11.26 million in the prior year.

Tone
Negative 30/100
Event
Earnings
Published
16 May 2026 07:40
Source
www.marketscreener.com
Moomoo Direct company coverage

H.C. Wainwright Downgrades Neuphoria Therapeutics(NEUP.US) to Hold Rating

H.C. Wainwright has downgraded Neuphoria Therapeutics (NEUP.US) to a Hold rating. No further details about the reasons for the downgrade were provided in this brief announcement.

Tone
Negative 32/100
Event
Analyst action
Published
15 May 2026 21:09
Source
Moomoo